Last reviewed · How we verify

NCT04934163

Flow Rates of High-flow Nasal Cannula and Extubation Outcome

Completed NA Last updated 10 May 2024
What this trial tests

NA trial testing Flow rate setting of high-flow nasal cannula (initially 60L/min) in Hypoxemic Respiratory Failure in 180 participants. Completed in 30 April 2023.

Timeline
1 September 2021
Primary endpoint
28 March 2023
30 April 2023

Quick facts

Lead sponsorNational Taiwan University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment180
Start date1 September 2021
Primary completion28 March 2023
Estimated completion30 April 2023
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

20 and older, any sex, with Hypoxemic Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open-label, randomized controlled trial to evaluate the effect of high-flow nasal cannula with a flow rate of 60 L/min versus 40 L/min after planned extubationon on a composite outcome of reintubation and use of NIV.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect of Flow Rates of High-Flow Nasal Cannula on Extubation Outcomes: A Randomized Controlled Trial.
    Ruan SY, Kuo YW, Huang CT, Chien YC, et al · · 2025 · PMID 39742913 · DOI 10.1016/j.chest.2024.12.021

Verify or expand the search:

Other recruiting trials for Hypoxemic Respiratory Failure

Currently open trials in the same condition.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04934163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing